CROSS-REACTIVITIES OF CYCLOSPORINE-G (NVA(2) CYCLOSPORINE) AND METABOLITES IN CYCLOSPORINE-A IMMUNOASSAYS

被引:0
|
作者
YATSCOFF, RW [1 ]
LANGMAN, LJ [1 ]
LEGATT, DF [1 ]
机构
[1] UNIV ALBERTA,DEPT LAB MED & PATHOL,EDMONTON T6G 2B7,AB,CANADA
关键词
INTERMETHOD COMPARISON; VARIATION; SOURCE OF; CYCLOSPORINE; CALIBRATION; MONITORING THERAPY; IMMUNOSUPPRESSIVE DRUGS;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Immunoassays of cyclosporin A (CsA) have been routinely used to measure CsG. We investigated the cross-reactivities of CsG and its metabolites, as well as the proportion CsG constitutes in relation to total drug measured, for six CsG metabolites (GM1, GM9, GM4N, GM1c, GM1c9, GM19) in the following CsA assays: Sandimmune selective RIA (SS), Sandimmune nonselective RIA (NS), Cyclotrac SP-RIA (CT), fluorescence polarization immunoassay (FPIA), and enzyme immunoassay (EMIT(TM)). The cross-reactivity of CsG in these assays was as follows: SS, FPIA, CT, approximately 100%; NS, approximately 40%; EMIT, < 2%. The cross-reactivities of CsG metabolites were investigated in all assays except EMIT and varied among metabolites and assays. The most significant variance was found with the NS assay, where most of the metabolites exhibited cross-reactivities of > 40%. In contrast, in the SS, FPIA, and CT assays, cross-reactivites of < 5% were observed for most of the metabolites. The ranking of cross-reactivites of CsG metabolites in the assays is SS = CT < FPIA < NS. The degree of cross-reactivity did not change significantly when the SS, CT, and FPIA assays were calibrated with CsG instead of CsA-whether parent CsG was present or not. The data suggest that the SS, CT, and FPIA methods would be suitable for the routine monitoring of CsG.
引用
收藏
页码:1089 / 1092
页数:4
相关论文
共 50 条
  • [41] DOES THE IMMUNOSUPPRESSANT FK-506 POSE A LESSER RISK TO BONE THAN CYCLOSPORINE-A OR CYCLOSPORINE-G
    CVETKOVIC, M
    ROMERO, D
    MANN, GN
    LIANG, XZ
    MA, WF
    JEE, W
    EPSTEIN, S
    JOURNAL OF BONE AND MINERAL RESEARCH, 1993, 8 : S340 - S340
  • [42] A COMPARISON OF THE IMMUNOSUPPRESSIVE EFFECTS OF CYCLOSPORINE A AND CYCLOSPORINE-G INVIVO AND INVITRO
    RAYAT, G
    YATSCOFF, R
    SILVERMAN, R
    MCKENNA, R
    TRANSPLANTATION, 1993, 55 (03) : 623 - 626
  • [43] MODULATION OF METABOLISM IN HEPG2 CELLS UPON TREATMENT WITH CYCLOSPORINE-A AND NVA2-CYCLOSPORINE
    BACKMAN, L
    APPELKVIST, EL
    SUNDBERG, A
    TECLEBRHAN, H
    BRUNK, U
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1991, 54 (03) : 242 - 254
  • [44] QUANTITATION OF CYCLOSPORINE-G BY RIA
    YATSCOFF, RW
    CLINICAL CHEMISTRY, 1986, 32 (06) : 1062 - 1063
  • [45] COMPARATIVE PHARMACOKINETICS OF CYCLOSPORINE AND NVA2-CYCLOSPORINE IN DOGS
    VENKATARAMANAN, R
    TODO, S
    ZAGHLOUL, I
    LYNCH, S
    KAM, I
    PTACHCINSKI, RJ
    BURCKART, GJ
    STARZL, TE
    TRANSPLANTATION PROCEEDINGS, 1987, 19 (01) : 1265 - 1266
  • [46] (NVA2)-CYCLOSPORINE - LESS POTENT THAN CYCLOSPORINE-A IN RATS WITH LUNG AND HEART-TRANSPLANTS
    PROP, J
    HOYT, EG
    JAMIESON, SW
    TRANSPLANTATION, 1987, 44 (01) : 5 - 8
  • [47] THE EFFECT OF FK-506, CYCLOSPORINE-A, AND CYCLOSPORINE-G ON SERUM 1,25-DIHYDROXYVITAMIN-D LEVELS
    JACOBS, TW
    KATZ, IA
    JOFFE, II
    STEIN, B
    TAKIZAWA, M
    EPSTEIN, S
    TRANSPLANTATION PROCEEDINGS, 1991, 23 (06) : 3188 - 3189
  • [48] COMPARISON OF CYCLOSPORINE-G (NVA(2)-CYCLOSPORINE) CONCENTRATIONS MEASURED IN WHOLE-BLOOD BY MONOCLONAL FLUORESCENCE POLARIZATION IMMUNOASSAY, MONOCLONAL RADIOIMMUNOASSAY, AND HPLC
    ANNESLEY, TM
    COOMBS, RC
    ORSULAK, PJ
    CLINICAL CHEMISTRY, 1993, 39 (06) : 1050 - 1053
  • [49] THE EFFECT OF CYCLOSPORINE-G (OG37-325), CYCLOSPORINE-A, AND THEIR METABOLITES ON THE RELEASE OF VASOACTIVE SUBSTANCES FROM PRIMARY RENAL-CELL LINES
    LANGMAN, LJ
    YATSCOFF, RW
    TRANSPLANTATION PROCEEDINGS, 1994, 26 (05) : 3002 - 3005
  • [50] DISSOCIATION BETWEEN RENIN-ANGIOTENSIN SYSTEM ACTIVATION AND HEMODYNAMIC DYSFUNCTION INDUCED BY CYCLOSPORINE-A AND CYCLOSPORINE-G IN THE RAT
    KASKEL, FJ
    CASELLAS, D
    MOORE, LC
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 999 - 999